MICA: ERADICATE HIV-1: TARGETING THE HIV-1 RESERVOIR WITH NEW IMMUNOTHERAPEUTIC STRATEGIES

Lead Research Organisation: University of Oxford
Department Name: Experimental Medicine

Abstract

There is no cure or vaccine for HIV infection. My aim is to explore new strategies for finding a cure for HIV infection. Thirty four million people are estimated to be infected with HIV - nearly 1% of the global adult population. Of these, 8 million are in receipt of antiretroviral therapy (also called 'ART'), but provision of ART to all who need it is a major logistical and financial challenge. Not only do patients have to stay on therapy for the rest of their lives, but there is the risk of drug resistance, side effects and stigma. We are also starting to learn that patients on ART develop other illnesses - such as heart disease, cancers and early dementia - that we do not fully understand. There is a growing understanding that although current HIV therapies have saved millions of lives, sustaining this for the future may demand new strategies. The most challenging of these is to find a cure for HIV.

HIV spreads widely in the human body in the first days after infection. Upon the use of potent ART the amount of residual virus declines dramatically. However, despite many years of continuous treatment the population of infected cells does not disappear completely - there is a 'reservoir' of infected cells. This tiny but dangerous reservoir of cells has the capacity to grow out and restore the original disease state. If all infected cells could be eradicated this would constitute a cure, but this has only been achieved in one individual and involved the radical step of bone marrow transplantation as well as potent chemotherapy - not a solution applicable to the millions of infected people.

The research will tackle key questions that need to be answered to achieve a cure for HIV. Can we wake up this 'reservoir' of infected cells so that the immune system can attack them? What is the best way to measure the 'reservoir' to assess if a patient might be cured? Are there patients who are more amenable to cure than others - in particular does treatment given very early after infection result in a period of 'remission' in which the patients can stop the drugs without the virus coming back?

The answer to any of these will impact the field significantly. The research will be carried out by Dr John Frater and his team at the University of Oxford, collaborating with researchers across the UK and internationally. The research will be a mixture of laboratory experiments to see how infected cells behave under different conditions and clinical studies in which samples from patients will be tested to try and understand how best to target the reservoir of persisting infected cells.

The studies will be conducted in three related workstreams. In the first, the researchers will study whether cells that contain silenced or 'latent' HIV can be 'woken up' using drugs normally used for cancer and whether the immune system will be able to recognise them. In the second workstream, a new test will be developed for measuring the reservoir using a combination of two techniques - one to measure the amount of viral DNA in the infected cells, and the other to use new genetic technologies to infer whether the viral genes can produce viable replicating viruses. Our aim is to develop and apply the technique, with the potential to bring it into clinical practice. Finally, in the third workstream, the researchers will develop new cohorts of patients treated very early in infection. Early treatment may be a key part of any cure, as the reservoir of infected cells at this stage looks more susceptible to new therapies. By developing these cohorts of adults and children, I aim to provide a platform to do this and conduct tests to see whether a cure might be feasible.

In summary, the research comprises an exciting series of objectives. The need for an HIV cure is great, and if proof-of-principle can be gained in any of these key directions, it would be a major step forward.

Technical Summary

There is no cure for HIV infection. The strategy of combining agents to activate the HIV viral reservoir in conjunction with immunotherapy is enticing as the most scalable approach to curing HIV. My aims are to prove the basic scientific justification for this strategy, through 3 key objectives:

1) 'To prove the antigenicity of latently infected cells'. I will expand our data showing that HIV-1 viral protein can be detected in latently-infected resting CD4 T cells, and that the proportion of cells producing protein can be increased using activators of transcription. Using unique immunological reagents - such as affinity-enhanced T cell receptors - I will demonstrate that viral proteins can be presented as antigens, leading to recognition and killing by T cells.

2) 'To develop and apply new assays for accurate measurement of the HIV-1 viral reservoir'. I will approach the problem that there is no gold standard assay that can be broadly applied to the measurement of the reservoir. I will utilise viral sequence data obtained using deep sequencing to infer the 'replication competent' reservoir. I will develop and apply Qualitative Quantitative PCR ('q2PCR' ) using cell lines, primary cell models and ex vivo patient samples.

3) 'To explore the enhanced potential for viral clearance in patients with Primary HIV-1 Infection (PHI)'. PHI is likely to be a critical time when the reservoir is most susceptible to intervention. Using newly established clinical PHI cohorts, I will explore how antiretroviral therapy (ART) when given in PHI - potentially in combination with other agents - might impact viral control and induce a state of remission, or 'post-treatment control'. Understanding PHI - and the impact of ART - would have a major bearing on strategies for eradicating HIV, and for guidelines on improved screening for patients.

The work will be undertaken at a centre with a world-class record in HIV immunology and in collaboration with industry partners.

Planned Impact

In the long-term, the research has the potential to impact at the global level, however I will also address the importance of the short- and medium-term objectives. The impact of a cure for HIV on patients, at-risk groups, health-care providers, policy makers, society and governments is clearly enormous. It is the landscape-changing nature of such an achievement that justifies (and demands) undertaking potentially high-risk research. There is a demand for such research from patient groups and representatives (Simon Collins, director of the major patient treatment activist group, i-base, sits on the steering committee of CHERUB) as well as from government (I presented on HIV Cure at a recent Department of Health workshop with the Chief Medical Officer, Dame Sally Davies).

A cure that is applicable to populations still remains years away. However, the proof of concept studies suggested in this proposal are critical and will impact the field and 'users' through the incremental steps in knowledge, methods and process that are required for such an undertaking.

There are 34 million people infected with HIV globally. In the UK around 100,000 individuals are HIV positive and rates of new infection are on the increase again. A cure for these users would allow patients to stop therapy, avoiding the risks of toxicity, drug resistance, stigmatisation and treatment fatigue that can lead to new transmissions and patient morbidity. The wider publicity attracted by cure research also has the impact of maintaining public awareness of HIV infection with the potential for safer sex practices and reduced transmission rates.

HIV costs the National Health Service approximately £1 billion per year. A cure has the potential to confer significant savings, although this will only be proven once the costs of any new treatments are clear.

In the shorter term, this Fellowship will be conducted in collaborations with Merck, Gilead and Adaptimmune, under fully executed Material Transfer Agreements. The commercial potential for using adapted TCRs (Adaptimmune) to target latently infected cells are significant, as are the applications of the drugs Vorinostat (Merck) and Romidepsin (Gilead) for HIV infection.

The development and validation of the q2PCR assay for reservoir quantification has commercial potential in clinical practice as well as the for the development of new bioinformatic pipelines for the analysis of deep-sequencing data and its incorporation into a clinical assay.

The discovery of new antigenic targets on latently infected cells has the potential to impact the HIV vaccine field. I already work closely with academic collaborators in Oxford (Hanke, Dorrell) and Okairos, with an application to the MRC for the REACH trial (under final review), the first proof-of-concept study of HDAC inhibitors plus vaccination in HIV infection. If vaccines can be used to target activated latent cells, this has the potential to open a new direction for HIV vaccination.

The studies of the new cohorts (HEATHER, RESPECT), as well as the already recruited SPARTAC cohort, will potentially impact treatment guidelines and strategies for assaying patients on therapy. If treatment in very early PHI can impact the reservoir and induce a state of 'post-treatment control' (as now suggested in a number of reports), confirmation of this in structured cohorts would impact screening programs to identify patients close to seroconversion, treatment guidelines to start ART as early as possible and assay development to measure the reservoirs (or other yet to be determined markers) in patients with possible induced control, and further assays (eg home testing) to allow regular monitoring of patients off therapy for virological rebound.

Publications

10 25 50

publication icon
Carlson JM (2016) Impact of pre-adapted HIV transmission. in Nature medicine

 
Title RHS Chelsea Royal Flower Show - HIV Garden 
Description Agreement with RHS for an HIV garden to be presented at the 2018 Chelsea flower show in collaboration with Terrence Higgins Trust to improve engagement with public around issues associated with living with HIV and how research is improving outcomes 
Type Of Art Artistic/Creative Exhibition 
Year Produced 2017 
Impact On-going 
 
Description British HIV Association Science and Education Sub-Committee
Geographic Reach Multiple continents/international 
Policy Influence Type Membership of a guideline committee
Impact Impact of HIV care guidelines in the UK and national HIV research portfolio
 
Guideline Title British HIV Association treatment guidelines
Description British HIV Association treatment guidelines 2015
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
URL http://www.bhiva.org
 
Guideline Title British HIV Association Treatment Guidelines 2016 update
Description Citations in British HIV Association Treatment Guidelines 2016 update
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
URL http://www.bhiva.org/guidelines.aspx
 
Description Engagement with iBase
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
Impact PAtient and public education around HIV from the ibase publication, website and Twitter feed
 
Description Membership of University Public Engagement Advisory Board
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Participation in a advisory committee
 
Description MRC CiC
Amount £66,647 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 01/2017 
End 12/2018
 
Description MRC Clinical Training Fellowship (for JT)
Amount £264,635 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 10/2015 
End 10/2018
 
Description MRC DCS
Amount £1,700,000 (GBP)
Funding ID MR/L00528X/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 11/2014 
End 10/2017
 
Description MRC Research Grant
Amount £450,593 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 01/2017 
End 12/2020
 
Description MRC Senior Clinical Fellowship
Amount £1,800,000 (GBP)
Funding ID MR/L006588/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 09/2014 
End 09/2019
 
Description NIHR Oxford BRC Renewal Round 3
Amount £320,000 (GBP)
Organisation Oxford University Hospitals NHS Foundation Trust 
Department NIHR Oxford Biomedical Research Centre
Sector Academic/University
Country United Kingdom
Start 04/2017 
End 04/2022
 
Description Nuffield Dept of Medicine Studentship (for GM)
Amount £107,333 (GBP)
Organisation University of Oxford 
Sector Academic/University
Country United Kingdom
Start 01/2015 
End 01/2019
 
Description Nuffield Dept of Medicine Studentship (for MJ)
Amount £86,000 (GBP)
Organisation University of Oxford 
Department Nuffield Department of Clinical Medicine
Sector Academic/University
Country United Kingdom
Start 10/2015 
End 10/2018
 
Description Public Engagement Grant
Amount £30,000 (GBP)
Organisation Viiv Healthcare 
Sector Private
Country United Kingdom
Start 01/2018 
End 06/2018
 
Description Public Engagement Grant
Amount £30,000 (GBP)
Organisation Gilead Sciences, Inc. 
Department Gilead
Sector Private
Country United Kingdom
Start 01/2018 
End 06/2018
 
Description RIO Clinical Trial: Set up award
Amount £90,267 (GBP)
Organisation Bill and Melinda Gates Foundation 
Sector Charity/Non Profit
Country United States
Start 10/2018 
End 09/2019
 
Description The PITCH Study Arm
Amount £199,999 (GBP)
Organisation amfAR, The Foundation for AIDS Research 
Sector Charity/Non Profit
Country United States
Start 10/2018 
End 09/2021
 
Description UCSF
Amount £66,497 (GBP)
Organisation Oxford Innovation Ltd 
Sector Private
Country United Kingdom
Start 01/2017 
End 12/2018
 
Description Using Genome Variation to Sort Extremely Rare Cell Populations for Clinical Application
Amount £59,529 (GBP)
Organisation Medical and Life Sciences Translational Fund 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2019 
End 03/2020
 
Title ATAC Seq 
Description Assay to determine transcriptional status of human genes. Assay was taught by collaborators at Harvard and work was carried out by a student GM in both Oxford and Harvard 
Type Of Material Technology assay or reagent 
Year Produced 2017 
Provided To Others? Yes  
Impact Paper submitted relating HIV therapy status and persistence to transcriptional activity 
 
Title HEATHER sample repository 
Description Samples of PBMCs and plasma from 250 patients with primary HIV infection 
Type Of Material Biological samples 
Provided To Others? No  
Impact Pending analysis 
 
Title Microfluidic sorting 
Description Assay developed to microfluidic droplets to enrich and sort very rare cell populations 
Type Of Material Technology assay or reagent 
Year Produced 2017 
Provided To Others? Yes  
Impact Working with Physical Chemistry this method is being optimised for clinical application. Patents currently being applied for 
 
Title PITCH sample repository 
Description Samples from participants undertaking antiretroviral therapy treatment interruptions 
Type Of Material Biological samples 
Year Produced 2018 
Provided To Others? Yes  
Impact Study on-going 
 
Title Sequencing bioinformatics 
Description Application of sureselect enrichment to rare DNA integrants in clinical samples 
Type Of Material Technology assay or reagent 
Year Produced 2018 
Provided To Others? No  
Impact The SOP for this method will be made available following publication This technique allows next gen sequencing of rare proviral HIV sequences - currently not possible consistently using present methodology Manuscript in preparation 
 
Title Single Genome HIV Proviral sequencing for bNAb sensitivity 
Description NGS assay to determine sensitivity of HIV isolates to bNAb neutralisation. Developed in collaboration with Rockefeller 
Type Of Material Technology assay or reagent 
Year Produced 2018 
Provided To Others? Yes  
Impact Identifying individuals who can receive bNAb therapy 
 
Title HEATHER database 
Description Collection of data regarding participants in the HEATHER HIV cohort 
Type Of Material Database/Collection of data 
Year Produced 2016 
Provided To Others? No  
Impact NIl as yet. Research protocols deriving from the database in preparation. 
 
Title PITCH Database 
Description Database of HIV+ individuals undertaking treatment interruptions 
Type Of Material Database/Collection of data 
Year Produced 2019 
Provided To Others? Yes  
Impact Study on-going 
 
Description AIDS Clinical Trials Group 
Organisation AIDS Clinical Trials Group (ACTG)
Country United States 
Sector Public 
PI Contribution UK representative of US ACTG HIV Cure strategy committee. Role is to explore new treatment strategies and studies, and to explore potential funding options.
Collaborator Contribution Monthly teleconferences to allow sharing of information and unpublished data to inform further research
Impact Sharing of data - multidisciplinary - virology/immunology/epidemiology/mathematical modelliing
Start Year 2016
 
Description Cepheid Inc 
Organisation Cepheid
Country United States 
Sector Private 
PI Contribution Testing of new diagnostics for point of care HIV monitoring
Collaborator Contribution Provision of equipment and training
Impact Abstract submitted to international meeting Further projects developed
Start Year 2016
 
Description Dept Of Physical Chemistry, University of Oxford 
Organisation University of Oxford
Department Physical and Theoretical Chemistry Laboratory
Country United Kingdom 
Sector Academic/University 
PI Contribution Research collaboration to develop microfluidic diagnostic platforms. Awarded MRC CiC grant and UCSF award.
Collaborator Contribution Partners bring expertise in microfluidics
Impact CIC Funding UCSF funding Patents pending
Start Year 2016
 
Description HEATHER Cohort 
Organisation Chelsea and Westminster Hospital NHS Foundation Trust
Country United Kingdom 
Sector Public 
PI Contribution Collaboration to recruit patients to a new cohort of patients with primary HIV infection
Collaborator Contribution Identification, recruitment and sampling of patients
Impact Recruitment of patients Sample repository in Oxford Public engagement meetings Oral abstract presentation at national and international meetings
Start Year 2015
 
Description HEATHER Cohort 
Organisation Imperial College School of Medicine
Country United Kingdom 
Sector Academic/University 
PI Contribution Collaboration to recruit patients to a new cohort of patients with primary HIV infection
Collaborator Contribution Identification, recruitment and sampling of patients
Impact Recruitment of patients Sample repository in Oxford Public engagement meetings Oral abstract presentation at national and international meetings
Start Year 2015
 
Description HEATHER Cohort 
Organisation St Thomas' Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution Collaboration to recruit patients to a new cohort of patients with primary HIV infection
Collaborator Contribution Identification, recruitment and sampling of patients
Impact Recruitment of patients Sample repository in Oxford Public engagement meetings Oral abstract presentation at national and international meetings
Start Year 2015
 
Description Harvard ATAC-Seq 
Organisation Harvard University
Department Harvard Medical School
Country United States 
Sector Academic/University 
PI Contribution Collaboration to run ATAC-Seq on HIV infected samples. My group provided samples and worked with the Harvard team to run the assay and interpret the data
Collaborator Contribution Provision of facilities and expertise
Impact Work in progress
Start Year 2017
 
Description Imperial and King's College 
Organisation Imperial College London
Department Department of Medicine
Country United Kingdom 
Sector Academic/University 
PI Contribution Contribute expertise, patient recruitment, strategy and laboratory assays to this NIHR collaboration
Collaborator Contribution Contribute expertise, patient recruitment, strategy and laboratory assays to this NIHR collaboration. Part of the evolution of the CHERUB network
Impact Multiple publications (listed), new collaborations (eg Rockefeller - listed) and new funding (detailed)
Start Year 2014
 
Description Imperial and King's College 
Organisation King's College London
Department Division of Immunology, Infection & Inflammatory Diseases (DIIID)
Country United Kingdom 
Sector Academic/University 
PI Contribution Contribute expertise, patient recruitment, strategy and laboratory assays to this NIHR collaboration
Collaborator Contribution Contribute expertise, patient recruitment, strategy and laboratory assays to this NIHR collaboration. Part of the evolution of the CHERUB network
Impact Multiple publications (listed), new collaborations (eg Rockefeller - listed) and new funding (detailed)
Start Year 2014
 
Description Oxford Martin School 
Organisation University of Oxford
Department Institute for Emerging Infections
Country United Kingdom 
Sector Academic/University 
PI Contribution Our research contributes bioinformatics and next generation sequencing analyses to answer questions around viral persistence. In my own group's case this is HIV, but the institute covers other pathogens such as HCV and HBV.
Collaborator Contribution Our partners bring bioinformatic expertise and mathematical modelling
Impact Multiple publications (see bibliography) New research proposals
Start Year 2012
 
Description PITCH cohort 
Organisation King's College London
Department NIHR Biomedical Research Centre
Country United Kingdom 
Sector Academic/University 
PI Contribution Collaborative team from Oxford, Cambridge, Imperial, UCL and King's. We provide trial protocol and sponsorship as well as assay platforms for sample analysis
Collaborator Contribution Recruitment of patients to the PITCH study
Impact Multi-disciplinary: GU medicine plus immunology and virology Ethical and HRA approvals received
Start Year 2016
 
Description RIO Clinical Trial 
Organisation Imperial College London
Department Faculty of Medicine
Country United Kingdom 
Sector Academic/University 
PI Contribution This is a new collaborative project funded by the Bill and Melinda Gates Foundation. Funding is pending but the grant is worth $6.5 million and should be confirmed by the end of March 2019. This is a collaboration between Oxford, Imperial and Rockefeller to run a clinical trial of neutralising antibody therapy to treat HIV in the UK.
Collaborator Contribution Rockefeller provides neutralising antibodies for the trial, Imperial provides clinical trial expertise and Oxford provides laboratory assays
Impact Set-up grant from BMGF Knowledge exchange for assays
Start Year 2018
 
Description RIO Clinical Trial 
Organisation Rockefeller University
Department Laboratory of Virology and Infectious Disease
Country United States 
Sector Academic/University 
PI Contribution This is a new collaborative project funded by the Bill and Melinda Gates Foundation. Funding is pending but the grant is worth $6.5 million and should be confirmed by the end of March 2019. This is a collaboration between Oxford, Imperial and Rockefeller to run a clinical trial of neutralising antibody therapy to treat HIV in the UK.
Collaborator Contribution Rockefeller provides neutralising antibodies for the trial, Imperial provides clinical trial expertise and Oxford provides laboratory assays
Impact Set-up grant from BMGF Knowledge exchange for assays
Start Year 2018
 
Description RIO Trial - Set Up award 
Organisation Rockefeller University
Country United States 
Sector Academic/University 
PI Contribution Sequence potential participants for the trial Develop the protocol
Collaborator Contribution Sponsorship Protocol development Knowledge exchange
Impact Knowledge exchange Assay development Development of full grant award
Start Year 2018
 
Description Rockefeller University 
Organisation Rockefeller University
Country United States 
Sector Academic/University 
PI Contribution Undertook screening of samples for antibody sensitiviries for clinical trial
Collaborator Contribution Developed technology and bioinformatics
Impact Grant funding Clinical trial
Start Year 2019
 
Title METHODS TO DETECT CELLS LATENTLY INFECTED WITH HIV 
Description The present invention provides a method of identifying a cell latently infected with HIV, wherein the method comprises: providing a sample of cells; encapsulating individual cells in droplets; screening for the presence of HIV derived DNA in the genomic DNA of encapsulated cells; and identifying, and optionally isolating, cells containing latent HIV derived DNA. 
IP Reference WO2019012270 
Protection Patent application published
Year Protection Granted 2019
Licensed No
Impact In process with OUI
 
Title Application of Cepheid viral load assay to POCT format in PITCH Clinical Trial 
Description We developed a protocol to adapt the Cepheid Viral Load assay to allow point of care testing with a single finger-prick blood sample rather than a full blood draw. This adaptation is not licensed but is being trialled in the PITCH study at present. The method is published. 
Type Diagnostic Tool - Non-Imaging
Current Stage Of Development Refinement. Clinical
Year Development Stage Completed 2018
Development Status Under active development/distribution
Impact This would be the first POCT finger-prick VL assay for HIV 
 
Description BBC News Channel Interview 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact BBC News interview on our Nature paper on the HIV cure of the London Patient
Year(s) Of Engagement Activity 2019
 
Description BBC Radio Podcasts 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Podcasts of science interviews
Year(s) Of Engagement Activity 2019
 
Description CHELSEA FLOWER SHOW HIV STIGMA GARDEN 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Garden presented at RHS Chelsea 2018. Themed on HIV Stigma. Won Silver Guilt Award. Huge national and international media attention. Prime time BBC1 TV report on the garden as well as national and international TV and Radio coverage. Handed out 10,000 leaflets on site. Estimated audience greater than 3 million
Year(s) Of Engagement Activity 2018
URL https://www.medsci.ox.ac.uk/cherub-hiv-garden
 
Description Cheltenham Science Festival 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Schools
Results and Impact Stand for NDM on HIV Cure at Cheltenham Science Festival
Year(s) Of Engagement Activity 2015
URL http://www.cherub.uk.net
 
Description Exhibit at Science Museum, London 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Display at Science Museum in London on CHERUB, its research outputs and prospects for an HIV Cure
Year(s) Of Engagement Activity 2015
URL http://www.cherub.uk.net
 
Description Facebook live interviews 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Two Facebook live interviews from RHS Chelsea to discuss HIV research in Oxford
Year(s) Of Engagement Activity 2018
URL https://www.facebook.com/OxSparks/videos/1670912232986397/
 
Description Facebook live interviews 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Interview with PhD students
Year(s) Of Engagement Activity 2018
URL https://www.facebook.com/OxSparks/videos/1670965162981104/
 
Description HEATHER participant meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Study participants or study members
Results and Impact Patient group meeting at Imperial College for HEATHER cohort
Year(s) Of Engagement Activity 2015,2016,2017
 
Description Podcast on HIV cure 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Podcast as part of Wellcome Trust project with 'A Gay and a Non-Gay'
Year(s) Of Engagement Activity 2020
 
Description Podcast on HIV stigma and research 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Podcast on the history of HIV, stigma and the search for a cure
Year(s) Of Engagement Activity 2018
URL https://www.oxfordsparks.ox.ac.uk/content/can-you-cure-hiv
 
Description RHS Chelsea HIV Garden - proposal accepted for 2018 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Proposal submitted to RHS for a garden dedicated to HIV therapy and cure for the 2018 Flower Show. Proposal accepted and work has commenced to raise funding
Year(s) Of Engagement Activity 2017
 
Description RIVER Trial Participant Meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact To inform and educate participants about the RIVER trial and its outcomes
Year(s) Of Engagement Activity 2018
URL http://www.cherub.uk.net